H5N1 News and Research

Latest H5N1 News and Research

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced positive results in a Phase 1 clinical trial for its oral, replicating adenovirus serotype 4 (Ad4) vector vaccine for H5N1 (avian flu).

31 Jan 2013

Cambodian health officials strengthen avian flu awareness campaigns after 2 more deaths

"Two more children have died in Cambodia of bird flu, bringing the number of fatal cases this year to four and the number of cases overall to five," the Associated Press/Wall Street Journal reports, noting only three cases were reported in all of 2012. "WHO says bird flu, also known as avian influenza, or H5N1, has killed 360 other people worldwide since surfacing in 2003," with most cases "linked to contact with infected poultry," the news agency writes.

30 Jan 2013

Have scientists thoroughly addressed avian flu research concerns?

Noting that a nearly yearlong moratorium on H5N1 avian influenza research, put in place "because of safety and terrorism concerns," was lifted recently, a New York Times editorial states, "We wish we could be as sanguine as they are that all the earlier concerns have been dealt with."

29 Jan 2013

New research sets out alternative approach to pandemic preparedness

'Evil' scientists, deadly viruses and terrorist plots are usually the preserve of Hollywood blockbusters. But when it comes to pandemic influenza, it is the stuff of real life. As controversy about research into the H5N1 bird flu virus continues, a new paper argues for a complete overhaul of current approaches to pandemic preparedness.

29 Jan 2013

Voluntary moratorium on H5N1 research ends; fate of U.S.-funded research unknown

"Almost a year after they announced it, leading influenza researchers are ending a voluntary moratorium on certain types of controversial experiments involving the H5N1 avian influenza virus."

25 Jan 2013

Yearlong moratorium on H5N1 research soon lifted, new rules implemented, Science reports

"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.

7 Jan 2013

NanoViricides to advance influenza drug candidate with completed $5M funding

NanoViricides, Inc., announced today that it has received the final tranche of $2.5M from Seaside 88, LP, thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.

25 Dec 2012

Voluntary moratorium on H5N1 avian flu research likely to end soon

Following the conclusion of a two-day meeting at the National Institutes of Health (NIH) this week -- meant "to gather feedback from flu researchers, others in the science community, and the public on its draft framework for funding H5N1 gain-of-function studies and to continue an international dialogue on issues related to benefits and risks of the research" -- "experts anticipated that a voluntary moratorium on work with lab-modified strains that have increased transmissibility might end soon," CIDRAP News reports.

21 Dec 2012

Researchers report seroprevalence of three avian flu virus strains in pigs in southern China

Researchers report for the first time the seroprevalence of three strains of avian influenza viruses in pigs in southern China, but not the H5N1 avian influenza virus. Their research, published online ahead of print in the Journal of Clinical Microbiology, has implications for efforts to protect the public health from pandemics.

20 Dec 2012

Meeting participants discuss HHS framework for funding H5N1 avian influenza research

CIDRAP News reports on a two-day meeting at the National Institutes of Health during which "researchers, biosecurity experts, and others" discussed the "crafting of a framework for funding H5N1 avian influenza gain-of-function studies." The meeting "is the latest chapter in an intense scientific controversy that was triggered by the publication of two recent studies involving lab-engineered H5N1 strains that showed signs of being transmissible in mammals," according to the news service.

19 Dec 2012

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

U.S. government's draft guidance on funding for H5N1 research receives 'mixed reception,' Science reports

"Researchers are giving a mixed reception to a draft U.S. government plan to do more stringent funding reviews of certain kinds of H5N1 avian influenza research -- and perhaps even require some studies to be kept secret," Science reports.

8 Dec 2012

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

28 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Single dose of Medicago's vaccine could offer cross-protection against flu

Researchers recently found that a single dose of a vaccine being developed by Medicago, Inc., a publicly traded biopharmaceutical company, could protect against not only the avian influenza (H5N1) strain it was designed for, but also another H5N1 strain and a strain of a different flu subtype, called H2N2.

22 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

Significant increase in genomic Replikin Count of human SARS virus

The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading. These concerns may be justified given the observed rise in virus's genomic Replikin Count.

6 Oct 2012

H5N1 News and Research

Latest H5N1 News and Research

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

Cambodian health officials strengthen avian flu awareness campaigns after 2 more deaths

Have scientists thoroughly addressed avian flu research concerns?

New research sets out alternative approach to pandemic preparedness

Voluntary moratorium on H5N1 research ends; fate of U.S.-funded research unknown

Yearlong moratorium on H5N1 research soon lifted, new rules implemented, Science reports

NanoViricides to advance influenza drug candidate with completed $5M funding

Voluntary moratorium on H5N1 avian flu research likely to end soon

Researchers report seroprevalence of three avian flu virus strains in pigs in southern China

Meeting participants discuss HHS framework for funding H5N1 avian influenza research

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

U.S. government's draft guidance on funding for H5N1 research receives 'mixed reception,' Science reports

CEL-SCI's Multikine cancer drug receives key Japanese patent

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

mRNA vaccines offer protection against influenza A virus infections in various animal models

Single dose of Medicago's vaccine could offer cross-protection against flu

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

Significant increase in genomic Replikin Count of human SARS virus

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

H5N1 News and Research

Latest H5N1 News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in